0001209191-23-046093.txt : 20230816
0001209191-23-046093.hdr.sgml : 20230816
20230816180537
ACCESSION NUMBER: 0001209191-23-046093
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230814
FILED AS OF DATE: 20230816
DATE AS OF CHANGE: 20230816
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jakobovits Aya
CENTRAL INDEX KEY: 0001823901
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38359
FILM NUMBER: 231179335
MAIL ADDRESS:
STREET 1: 3135 HUTTON DRIVE
CITY: BEVERLY HILLS
STATE: CA
ZIP: 90210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adicet Bio, Inc.
CENTRAL INDEX KEY: 0001720580
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813305277
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-482-2333
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 19TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: resTORbio, Inc.
DATE OF NAME CHANGE: 20171024
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2023-08-14
0
0001720580
Adicet Bio, Inc.
ACET
0001823901
Jakobovits Aya
C/O ADICET BIO, INC.
200 BERKELEY STREET, 19TH FLOOR
BOSTON
MA
02116
1
0
0
0
0
Stock Option (Right to Buy)
16.11
2023-08-14
4
D
0
30000
0.00
D
2030-09-16
Common Stock
30000
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
30000
0.00
A
2030-09-16
Common Stock
30000
30000
D
Stock Option (Right to Buy)
15.93
2023-08-14
4
D
0
18500
0.00
D
2031-04-29
Common Stock
18500
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
18500
0.00
A
2031-04-29
Common Stock
18500
18500
D
Stock Option (Right to Buy)
11.49
2023-08-14
4
D
0
18500
0.00
D
2032-06-01
Common Stock
18500
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
18500
0.00
A
2032-06-01
Common Stock
18500
18500
D
Stock Option (Right to Buy)
5.195
2023-08-14
4
D
0
26400
0.00
D
2033-05-31
Common Stock
26400
0
D
Stock Option (Right to Buy)
2.14
2023-08-14
4
A
0
26400
0.00
A
2033-05-31
Common Stock
26400
26400
D
On August 8, 2023, the Issuer's Board of Directors approved an option repricing (the "Repricing"), effective as of August 14, 2023 (the "Effective Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
The shares subject to this option shall vest in thirty-six (36) equal monthly installments commencing on September 17, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
The exercise price of the option is $2.14 per share, representing the fair market value per share of the Issuer's Common Stock on the Effective Date; provided that the repriced option will revert to its original exercise price if, prior to the first anniversary of the Effective Date, (a) the Reporting Person's service on the Issuer's Board of Directors is terminated by the Issuer with cause or by the Reporting Person or (b) the option is exercised.
The shares subject to this option are fully vested and exercisable as of the date hereof.
The shares subject to this option shall vest in full on the earlier to occur of (a) June 1, 2024 or (b) the date of the Issuer's 2024 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors as of the applicable vesting date.
/s/ Nick Harvey, Attorney-in-Fact
2023-08-16